Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50%
In patients with NSCLC and PD-L1 ≥50% showing primary resistance to first-line ICI, continuing immunotherapy beyond progression combined with chemotherapy may improve survival outcomes. These findings should be considered hypothesis-generating and warrant prospective confirmation.
Authors
- Lizza Hendriks (ORCID: https://orcid.org/0000-0002-3521-2535)
- Silvia Novello (ORCID: https://orcid.org/0000-0001-7653-9748)
- Laura Mezquita (ORCID: https://orcid.org/0000-0003-0936-7338)
- B. Besse
- Francesco Gelsomino (ORCID: https://orcid.org/0000-0002-9204-1728)
- Andrea Ardizzoni (ORCID: https://orcid.org/0000-0003-2678-0714)
- Massimiliano Cani (ORCID: https://orcid.org/0000-0001-9608-4840)
- Valentina Favorito (ORCID: https://orcid.org/0009-0001-5282-260X)
- Fabrizio Tabbò (ORCID: https://orcid.org/0000-0001-8525-2992)
- Filippo Gustavo Dall’Olio (ORCID: https://orcid.org/0000-0003-0903-6109)
- T. Gorria
- Francesco Mantuano (ORCID: https://orcid.org/0009-0005-3111-5067)
- Mihaela D. Aldea (ORCID: https://orcid.org/0000-0001-7685-051X)
- Davide Soldato
- Alessandro Di Federico (ORCID: https://orcid.org/0000-0001-8877-4315)
- Francesca Sperandi (ORCID: https://orcid.org/0000-0002-1581-3456)
- Andrea De Giglio (ORCID: https://orcid.org/0000-0002-0731-5721)
- A. Sadowska
- L Zullo
Institutions
- Breast Cancer Research Foundation (US)
- Maastricht University Medical Centre (NL)
- Institut Gustave Roussy (FR)
- Hospital Clínic de Barcelona (ES)
- Azienda USL di Bologna (IT)
- Ospedale Policlinico San Martino (IT)
- Ospedale San Luigi Gonzaga (IT)
- Ospedale San Pietro Fatebenefratelli (IT)
- Universitat de Barcelona (ES)
- University of Bologna (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105897
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission